GH secretagogues: oral vs injectable

Ipamorelin vs MK-677

Comparing Ipamorelin and MK-677 across evidence, dosing, mechanisms, and research areas.

Compound A

vs

Compound B

Category

growthhormone

hormone

Molecular weight

711.85 g/mol

—

Half-life

~2 hours

—

Admin routes

subcutaneousintravenous

—

Research areas

Growth hormone optimizationBody compositionSleep qualityRecoveryPostoperative ileusAnti-emetic effectsBone density

—

Typical dosing

200–300 mcg · 1-3x daily · 8-12 weeks

—

FDA status

Not FDA-approved. Category 2 (under evaluation for 503A compounding)

research-only

WADA status

Prohibited (S2 — peptide hormones, growth factors, and related substances)

—

PubMed studies

49

—

Full profile →Full profile →

More Comparisons

bpc-157 vs tb-500 cjc-1295 vs ipamorelin semaglutide vs tirzepatide ghk-cu vs ghk ghrp-2 vs ghrp-6 igf-1-lr3 vs igf-1-des semax vs selank epithalon vs ghk-cu bpc-157 vs ghk-cu pt-141 vs kisspeptin semaglutide vs aod-9604 tirzepatide vs mk-677 bpc-157 vs cerebrolysin tesamorelin vs cjc-1295 thymosin-alpha-1 vs ll-37 mots-c vs nad-plus cerebrolysin vs semax epithalon vs nad-plus semaglutide vs retatrutide